Jeffrey William Henderson, a director at Becton Dickinson & Co (NYSE:BDX), recently acquired 1,500 shares of the company's common stock. The purchase, which took place on February 10, 2025, was made ...

BD recently issued a medical device correction later related to its Bard subsidiary's Rotarex atherectomy system.

The FDA is getting the word out on a high-risk issue related to artery-clearing catheters from BD’s Bard Peripheral Vascular ...

According to the company, medical essentials and interventional lead the medical technology unit's business lines, bringing ...

Last week, readers were most interested in a story about BD's plan to separate its Biosciences and Diagnostics Solutions business by the end of 2026.

Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

William Blair analyst A. Brackmann anticipates that the medical instruments supplier will post earnings of $3.34 per share for […] ...

GlobalData’s director of therapy research & analysis in medical devices says the new entity could make an attractive ...

CEO Tom Polen said BD will “double down on shifting our portfolio, both organically and inorganically through tuck-in M&A, ...

Greg Rodetis; Senior Vice President, Treasurer and Head of Investor Relations; Becton Dickinson and Co Thomas Polen; Chairman of the Board, President, Chief Executive Officer; Becton Dickinson and Co ...

Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.